糖尿病肾病纤溶酶原激活物抑制因子-1检测分析  

Plasminogen activator inhibitor-1 test in diabetic nephropathy patients

作　　者：李曦光[1] 刘晓云[1] 陈黎忠[1] 徐转[1] 

机构地区：[1]蚌埠医学院第二附属医院,安徽蚌埠233040

出　　处：《吉林医学》2011年第20期4067-4068,共2页Jilin Medical Journal

摘　　要：目的:探讨糖尿病肾病患者血浆纤溶酶原激活物抑制物的变化。方法:检测33例糖尿病肾病患者及30例健康体检对照组血浆纤溶酶原激活物抑制物-1(PAI-1),观察检测结果。结果:33例糖尿病肾病患者纤溶酶原激活物抑制物-1(PAI-1)检测值(51.7±12.5)ng/ml,明显高于对照组检测值(27.1±11.2)ng/ml(P<0.01)。结论:糖尿病肾病患者存在血浆纤溶酶原激活物及其抑制物系统失衡。Objective To investigate the plasminogen activator inhibitor changes in patients with diabetic nephropathy.Method Plasminogen activator inhibitor-1（PAI-1） in 33 cases of diabetic nephropathy and 30 healthy controls were detected,and the test results were observed.Results The plasminogen activator inhibitor-1（PAI-1） level in 33 patients with diabetic nephropathy was（51.7±12.5） ng/ml,was significantly higher than that in the control group（27.1±11.2） ng/ml（P0.01）.Conclusion The diabetic nephropathy patients have imbalance of plasma plasminogen activator and its inhibitor system.

关 键 词：糖尿病肾病 血浆纤溶酶原激活物抑制物-1 

分 类 号：R587.2[医药卫生—内分泌]